PAINCHEK Stock Australian S.E.

Equities

PCK

Software

End-of-day quote Australian S.E. 5-day change 1st Jan Change
- AUD -.--% Intraday chart for PAINCHEK -.--% -.--%
Sales 2022 994K 650K Sales 2023 1.96M 1.28M Capitalization 32.45M 21.22M
Net income 2022 -5M -3.27M Net income 2023 -7M -4.58M EV / Sales 2022 28.7 x
Net cash position 2022 6.14M 4.02M Net cash position 2023 2.51M 1.64M EV / Sales 2023 15.3 x
P/E ratio 2022
-5.52 x
P/E ratio 2023
-4.26 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 66.56%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer - 16-09-29
Director of Finance/CFO - 21-03-21
Chief Operating Officer - 20-11-30
Members of the board TitleAgeSince
Chairman 65 16-09-29
Director/Board Member 79 16-09-29
Director/Board Member - 14-09-29
More insiders
PainChek Ltd is an Australia-based company, which develops pain assessment technologies. The Company’s principal activities are development and commercialization of mobile medical device applications that provide pain assessment for individuals that are unable to communicate with their carers. The Company’s PainChek Universal is a complete point-of-care solution that combines the existing PainChek Application with the numerical rating scale (NRS). PainChek Application uses artificial intelligence and facial recognition to detect pain in those who cannot self-report. This gives a voice to those who cannot verbalize pain, whilst also driving objectivity and consistency in all assessments. For those who can self-report, PainChek Universal also includes access to the NRS, a standard used to document pain levels amongst these individuals. PainChek Universal also supports pain assessment using both tools at the point of care, for those people whose ability to communicate fluctuates.
More about the company

Annual profits - Rate of surprise